# ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

> **NCT05056896** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 161 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Aspirin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05056896
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-03
- **Primary completion:** 2024-11-27
- **Final completion:** 2026-12-31
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056896, "ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05056896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*